CORTANCYL 20 mg

DRUG9 trials

Sponsors

French Innovative Leukemia Organization, Lysarc, Hopital Fondation Adolphe De Rothschild, CHRU De Nancy, Centre Hospitalier Universitaire De Dijon

Conditions

ANCA vasculitisAdults patients with isolated acute urticaria presenting to the emergency departmentCholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)End-stage Renal diseaseGIant cell ArteritisMen and women over 18 years of age with renal failure renal failure stages 3b/4/5Myasthenia gravisPatients with previously untreated Richter’s syndrome (RS)

Phase 2

FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY

RecruitingCTIS2022-501554-11-00

French Innovative Leukemia Organizationdefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology., Patients with previously untreated Richter’s syndrome (RS)

Start: 2024-03-21Target: 40Updated: 2025-12-24

A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporeal photopheresis as first-line treatment of Grade II acute graft-versus-host disease with skin involvement occuring after allogeneic stem cell transplantation - COPAVEHDI

RecruitingCTIS2023-508614-41-00

CHRU De Nancyin transplant centers contributing to this trial (departments of hematology)., The study will be proposed to all adult patients receiving an allogeneic hematopopietic stem cell transplantation and presenting a Grade II acute GVH with skin +/- upper gastrointestinal involvement

Start: 2024-10-15Target: 78Updated: 2025-10-07

Phase 3

MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial

Active, not recruitingCTIS2024-512269-14-00

Centre Hospitalier Universitaire De DijonGIant cell Arteritis

Start: 2020-01-27Target: 230Updated: 2025-11-21

Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, randomized controlled trial

RecruitingCTIS2023-506656-24-00

Hopital Fondation Adolphe De RothschildMyasthenia gravis

Start: 2025-02-12Target: 128Updated: 2025-06-06

Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial

RecruitingCTIS2024-512470-10-00

Centre Hospitalier Departemental VendeeANCA vasculitis, End-stage Renal disease

Start: 2018-02-02Target: 136Updated: 2026-01-22

COURAGE - Corticosteroid in acute urticaria in emergency department

CompletedCTIS2024-515308-38-00

Assistance Publique Hopitaux De ParisAdults patients with isolated acute urticaria presenting to the emergency department

Start: 2019-09-21End: 2025-09-17Target: 240Updated: 2024-08-13

ANA4CKD - Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease stage 4-5 or kidney transplantation

CompletedCTIS2024-514347-28-00

Assistance Publique Hopitaux De ParisMen and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack

Start: 2022-06-02End: 2025-02-12Target: 234Updated: 2024-10-21

Efficacy of Ursodeoxycholic Acid versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial

Not yet recruitingCTIS2025-521317-50-00

Centre Hospitalier Universitaire De MontpellierCholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)

Target: 94Updated: 2025-11-17

Phase 4

TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma

RecruitingCTIS2022-501710-62-02

LysarcPeripheral T-cell lymphoma (PTCL)

Start: 2023-06-07Target: 204Updated: 2026-01-19